EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

T2‐Fluid‐attenuated inversion recovery (FLAIR) pseudoprogression in patients with anaplastic oligodendrogliomas treated with procarbazine, lomustine and vincristine (PCV) chemotherapy alone

Inés Esparragosa Vazquez iD, Mané Ndiaye, Anna Luisa Di Stefano, Nadia Younan, Delphine Larrieu-Ciron, Antoine Seyve, Thiébaud Picart, David Meyronet, Claire Boutet, François Vassal, Catherine Carpentier, Dominique Figarella-Branger und 5 weitere

European Journal of Neurology · 2023

DOI: 10.1111/ene.15873 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Neurology, 2023. Verfasst von Inés Esparragosa Vazquez und 16 weiteren Autor:innen. Beteiligte Einrichtung: Neuro-Oncology Department, Hospices Civils of Lyon, Lyon, France. Hauptthemen laut MEDLINE: Oligodendroglioma, Brain Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 9 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: European Academy of Neurology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Pseudoprogression in gliomas has been extensively described after radiotherapy with or without chemotherapy, but not after chemotherapy alone. Here we describe the occurrence of pseudoprogression in patients with anaplastic oligodendrogliomas treated with postoperative procarbazine, lomustine and vincristine (PCV) chemotherapy alone.

Methods

We retrospectively reviewed the medical and radiological files of patients with 1p/19q codeleted, IDH‐mutant anaplastic oligodendrogliomas treated with PCV chemotherapy alone who presented magnetic resonance imaging (MRI) modifications suggestive of tumour progression and in whom the final diagnosis was a pseudoprogression.

Results

We identified six patients. All patients underwent a surgical resection and were treated with PCV chemotherapy without radiotherapy. After a median of 11 months following the initiation of chemotherapy (range: 3–49 months), the patients developed asymptomatic white matter MRI modifications around the surgical cavity leading to the suspicion of a tumour progression. These modifications appeared as hyperintense on T2‐fluid‐attenuated inversion recovery (FLAIR) sequence, hypointense on T1 sequence, and lacked mass effect (0/6), contrast enhancement (0/6), restriction on diffusion‐weighted imaging (0/4), relative cerebral blood volume (rCBV) increase on perfusion MRI (0/4), and hypermetabolism on 18 F‐fluoro‐L‐dopa positron emission tomography ( 18 F‐DOPA PET) scan (0/3). One patient underwent a surgical resection demonstrating no tumour recurrence; the five other patients were considered as having post‐therapeutic modifications based on imaging characteristics. After a median follow‐up of 4 years all patients were progression‐free.

Conclusions

Anaplastic oligodendroglioma patients treated with postoperative PCV chemotherapy alone occasionally develop T2/FLAIR hyperintensities around the surgical cavity that can wrongly suggest tumour progression. Multimodal imaging and close follow‐up should be considered in this situation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OligodendrogliomaBrain NeoplasmsHumansLomustineVincristineProcarbazineRetrospective StudiesAntineoplastic Combined Chemotherapy ProtocolsNeoplasm Recurrence, LocalMagnetic Resonance Imaging

Stichwörter der Autor:innen

PCV chemotherapyanaplastic oligodendrogliomapseudoprogressionradiotherapy

Substanzen

LomustineVincristineProcarbazine

Autor:innen und Institutionen

  • Neuro-Oncology Department, Hospices Civils of Lyon, Lyon, France.
  • Neuro-Oncology Department, Centre Georges François Leclerc, Dijon, France.
  • Neuro-Oncology Department, Hôpital Foch, Suresnes, France.
  • Neuro-Oncology Department, Institut Universitaire du Cancer de Toulouse, Toulouse, France.
  • Neuro-Surgery Department, Hospices Civils of Lyon, Lyon, France.
  • Neuropathology Department, Hospices Civils of Lyon, Lyon, France.

ORCID-Profile: Inés Esparragosa Vazquez

Förderung

  • European Academy of Neurology

Zitieren

APA

Esparragosa Vazquez, I., Ndiaye, M., Di Stefano, A. L., Younan, N., Larrieu-Ciron, D., Seyve, A., Picart, T., Meyronet, D., Boutet, C., Vassal, F., Carpentier, C., Figarella-Branger, D., Dehais, C., Forest, F., Rivoirard, R., Ducray, F., & POLA network (2023). T2‐Fluid‐attenuated inversion recovery (FLAIR) pseudoprogression in patients with anaplastic oligodendrogliomas treated with procarbazine, lomustine and vincristine (PCV) chemotherapy alone. European Journal of Neurology. https://doi.org/10.1111/ene.15873

Vancouver

Esparragosa Vazquez I, Ndiaye M, Di Stefano AL, Younan N, Larrieu-Ciron D, Seyve A, et al. T2‐Fluid‐attenuated inversion recovery (FLAIR) pseudoprogression in patients with anaplastic oligodendrogliomas treated with procarbazine, lomustine and vincristine (PCV) chemotherapy alone. European Journal of Neurology. 2023. doi:10.1111/ene.15873

BibTeX
@article{EsparragosaVazquez2023,
  author = {Esparragosa Vazquez, Inés and Ndiaye, Mané and Di Stefano, Anna Luisa and Younan, Nadia and Larrieu-Ciron, Delphine and Seyve, Antoine and Picart, Thiébaud and Meyronet, David and Boutet, Claire and Vassal, François and Carpentier, Catherine and Figarella-Branger, Dominique and Dehais, Caroline and Forest, Fabien and Rivoirard, Romain and Ducray, François and POLA network, POLA network},
  title = {T2‐Fluid‐attenuated inversion recovery (FLAIR) pseudoprogression in patients with anaplastic oligodendrogliomas treated with procarbazine, lomustine and vincristine (PCV) chemotherapy alone},
  journal = {European Journal of Neurology},
  year = {2023},
  doi = {10.1111/ene.15873}
}
Kostenlos starten →